Associated Papers
Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma.
Huang CY et al.
Bmc Cancer, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Corrigendum to "POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases": [Modern Pathology 38 (2025) 100676].
Hammer PM et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases.
Hammer PM et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy.
Huang J et al.
Frontiers in Immunology, 2025
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications.
Gupta I et al.
Seminars in Cancer Biology, 2024
DICER1-sarcomas of GYN tract: Expanding on an emerging entity.
Dashti NK et al.
Human Pathology, 2024
Clinical phenotype of the PIK3R1-related vascular overgrowth syndrome.
Kuentz P et al.
The British Journal of Dermatology, 2024
Unravelling the role of PLK1 in tumorigenesis by revealing the mutational landscape of colorectal and lung cancer with PLK1 mutations.
Wang S et al.
Journal of Cellular and Molecular Medicine, 2024
Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas.
Pu X et al.
Cell & Bioscience, 2023
Proteogenomic insights suggest druggable pathways in endometrial carcinoma.
Dou Y et al.
Cancer Cell, 2023
Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery.
Hossain MA et al.
Plos One, 2023
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
Zhang Y et al.
Neuro-oncology, 2022
BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression.
Kang SY et al.
International Journal of Molecular Sciences, 2022
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.
Shi DD et al.
Cancer Cell, 2022
A novel mutant PIK3R1EY451delinsD breast cancer patient resistant to HER2-targeted therapy treated with everolimus: a case report.
Wang K et al.
Molecular Biology Reports, 2022
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF et al.
Genome Medicine, 2022
Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.
Nussinov R et al.
Molecular Cancer Research : Mcr, 2021
Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population.
Saadeh FS et al.
Plos One, 2020
Neomorphic mutations create therapeutic challenges in cancer.
Takiar V et al.
Oncogene, 2017
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.
Cheung LW et al.
Cancer Cell, 2014
PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Cizkova M et al.
Bmc Cancer, 2013
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW et al.
Cancer Discovery, 2011
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Unknown Author
Nature, 2008